Home Blog Page 1294

Railtown AI Technologies Announces $3.4M Private Placement Lead by BlackBerry Co-Founders Mike Lazaridis and Doug Fregin, with Lazaridis Joining Advisory Board to Drive Canadian Innovation

By
Advertorial Desk
-
***NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES.***

Vancouver, British Columbia – Newsfile Corp. – February 10, 2026 – Railtown AI Technologies Inc. (CSE: RAIL) (“Railtown” or the “Company“), a Canadian company building advanced AI developer and agentic platforms, announces that Mike Lazaridis, co-founder of Research In Motion (now known as BlackBerry), has joined Railtown’s Advisory Board and along with fellow co-founder Doug Fregin, is leading a $3.4 million private placement in Railtown (the “Private Placement”), further supporting the company’s growth and mission to develop Canadian AI talent and technology.

The Private Placement consists of up to 11,333,334 units of the Company (each, a “Unit“) at a price of $0.30 per Unit, with each Unit comprised of one common share in the capital of Railtown (each, a “Share“) and one-half of one common share purchase warrant (each whole warrant, a “Warrant“). Each Warrant is exercisable into one (1) Share at a price of $0.45 per Share for a period of 18 months from the date of issuance, subject to acceleration in certain limited circumstances.

Mr. Lazaridis and Mr. Fregin are two of Canada’s most accomplished technology entrepreneurs who pioneered the modern smartphone industry. They grew Research In Motion from a startup into one of Canada’s most successful technology companies with $19 billion in annual revenues, 18,000 employees worldwide, and a peak market value of $68 billion.

Railtown’s mission, through its Agent Development Platform and collaborations with TELUS and other Canadian AI data hosting providers, is to create a Canadian-focused AI development and deployment ecosystem which aligns closely with both Mr. Lazaridis’ and Mr. Fregin’s long-standing commitment to building and retaining world-class technology talent in Canada.

“Canada develops exceptional talent, but too many feel they have to leave the country to pursue meaningful opportunities,” said Mr. Lazaridis. “It’s critical that we build companies, platforms, and ecosystems here that allow Canadians to innovate, grow, and compete globally. Railtown is building foundational AI technology in Canada, and I’m excited to support that vision.”

In addition to their entrepreneurial achievements, both Mr. Lazaridis and Mr. Fregin have been a driving force behind Canada’s leadership in advanced science and deep technology. Between the two of them, they are founding partners of Quantum Valley Investments, the Institute for Quantum Computing, the Perimeter Institute for Theoretical Physics, and Quantum Valley Ideas Lab – institutions that have helped position Canada as a global centre for quantum research and commercialization.

Railtown’s focus on Canadian AI sovereignty, including secure, transparent, developer-centric AI infrastructure and agent platforms, closely reflects these values.

“Having spent time working in Silicon Valley, I’ve seen firsthand how powerful a strong technology ecosystem can be,” said Cory Brandolini, CEO of Railtown. “In the Valley, many of the most successful founders lead by example-actively investing in the next generation of startups, sharing hard-earned experience, and providing valuable advisory insight. That culture of reinvestment is a major reason the ecosystem continues to thrive.”

“Mike and Doug’s decision to invest in Railtown sends a powerful signal about what’s possible when experienced Canadian founders support the next wave of innovation. This investment, along with Mike’s involvement on the Advisory Board will add invaluable strategic guidance, reinforcing Railtown’s mission to build a globally competitive AI company from Canada.”

As described above, the Warrants issuable in Private Placement are subject to acceleration such that if, during a period of 10 consecutive trading days prior to their expiry date, the daily volume-weighted average trading price of the Shares on the Canadian Securities Exchange (the “CSE“) or such other stock exchange where the majority of the trading volume occurs, exceeds $0.90 for each of those 10 consecutive days, the Company may, within 30 days of such an occurrence, give written notice to the holders of the Warrants that the securities will expire at 5:00 p.m. (Vancouver time) on the 30th day following the giving of notice unless exercised by the holders prior to such date. Any Warrants which remain unexercised at 5:00 p.m. (Vancouver time) on the 30th day following the giving of such notice will expire at that time.

The Company intends to use the proceeds of the Private Placement for general working capital purposes and may pay finder’s fees to eligible finders in the form of cash and/or common share purchase warrants. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the CSE.

All securities issued in connection with the Private Placement will be subject to a standard hold period of four months and one day in accordance with applicable Canadian securities laws.

None of the securities referenced in this news release have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any applicable state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) or persons in the United States absent registration or an applicable exemption from such registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Railtown

Railtown AI Technologies Inc. builds AI developer tools and agentic frameworks that power the next generation of intelligent applications. Its Platform – including real-time ingestion (Railengine), agent development frameworks (Railtracks ADK), and advanced observability (Conductr) – helps teams build, deploy, and operate AI agents with confidence and at scale.

For more information, visit www.railtown.ai.

Follow us on social media

SUBSCRIBE FOR INVESTOR NEWS

Click here to receive our latest investor news alerts.

ON BEHALF OF THE BOARD
“Cory Brandolini”
Cory Brandolini, Chief Executive Officer

INVESTOR CONTACT

Rebecca Kerswell
Investor Relations Contact
Email: investors@railtown.ai
Phone: 1-604-417-4440

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the anticipated closing of the Private Placement, the use of proceeds from the Private Placement, and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

The issuer is solely responsible for the content of this announcement.

AI Didn’t Break the Workforce. Bad Implementation Did.

By
Advertorial Desk
-

As headlines are dominated by AI-driven workforce restructuring, a deeper enterprise risk is emerging: organizations that fail to design human-AI collaboration into daily work are eroding productivity, speed, and competitiveness. Datatonic says the next phase of enterprise AI will be defined not by automation alone, but by governed, human-in-the-loop systems that turn AI into a workforce multiplier.

LONDON, Feb. 10, 2026 /PRNewswire/ — Public debate around artificial intelligence has been dominated by workforce reduction, but for enterprise leaders, the real threat is more subtle yet more damaging. Companies that fail to embed AI into human workflows are falling behind as productivity stalls; decision cycles stretch, and competitors move faster with hybrid human-AI operating models.

“AI isn’t just about replacing tasks. It’s about redesigning how work gets done,” said Scott Eivers, CEO of Datatonic. “The biggest risk we see in the market is productivity leakage when AI exists in isolation from the people who actually run the business.”

Boards and executive teams are entering 2026 under pressure to show returns on years of AI investment. Yet, according to Massachusetts Institute of Technology research reported in Fortune, as many as 95% of AI pilots are not pulling their weight. Many initiatives stay trapped in pilot mode, disconnected from core operations and governed poorly enough to limit trust among users. The result: AI systems generating insights that are never translated into action, leaving human teams to carry the same — or greater — operational burden as pre-AI times.

From Replacement Narratives to Real Collaboration 

Datatonic’s work with global enterprises shows that the most effective AI programs are not yet fully autonomous. Instead, they are built around human-in-the-loop (HiTL) models that combine AI’s speed with human judgment, accountability, and domain expertise.

One of the most mature examples is agent-assisted software development. Enterprises have moved beyond “vibe coding,” where AI generates code from loose prompts to spec-driven development models. In these environments, humans define, validate and even test the specification and execution plan before AI agents build modular features at scale, accelerating delivery without sacrificing control.

A similar pattern is emerging across finance, operations, and customer workflows.

  • Streamlined Data Operations: GenOps workflows, where humans and AI agents collaborate to streamline data operations. The result: less manual effort, while approvals, exception handling, and escalation stay with humans.
  • Finance Automation: For back-office and finance departments, AI-driven document processing is achieving up to a 70% reduction in invoice-processing costs whilst ensuring finance teams retain approval authority and anomaly resolution.

“These aren’t replacement stories,” said Andrew Harding, CTO of Datatonic. “They’re partnership stories. Humans create evaluation systems, validate plans, set guardrails, and make decisions. AI executes at speed and scale. That combination is where real enterprise value shows up.”

Trust, Governance, and the Path to Autonomy 

Despite hype around fully autonomous agents, Datatonic warns that most enterprises lack the operational maturity to deploy them safely. Critical gaps remain in agent supervision, security controls, and governance frameworks that define what AI systems can access, process, and change. Agents should operate in secure, enterprise approved shared-runtime environments which automatically mandate organisational policy whilst supporting governance and observability.

Before autonomy can scale, organizations must implement clear boundaries, approval checkpoints, and performance baselines. As models evolve, evaluation systems are essential to ensure AI continues to operate as intended, while guardrails protect against unintended actions or non-compliant outputs.

“As trust builds, companies can responsibly delegate more to AI,” Harding said. “But skipping governance doesn’t build speed — it creates risk.”

Measuring What Matters 

For enterprises under board scrutiny, success is no longer measured by novelty. Datatonic advocates for clearly documented ROI for every AI system, tied to quantifiable business outcomes, including reduced churn, faster cycle times, or measurable cost savings. Where possible, performance data should be embedded directly into agent platforms so leaders can see, in real time, whether AI is delivering on its promise.

Looking ahead 12 to 24 months, Datatonic expects enterprise work to compress from weeks to hours as agents handle preparation, analysis, and validation. Meetings will shift from status updates to decision-making. In some cases, AI agents will be used to test and invalidate ideas before teams commit resources.

“The future looks like expert departments run by smaller, nimble teams – finance, HR, marketing – each amplified by AI. It’s about higher leverage.” Eivers said. 

Future AI Action 

For enterprise and business leaders planning their next AI phase, Datatonic urges a reset: move beyond replacement narratives and invest in human-centered, governed AI systems that integrate directly into how work happens. 

“The companies that win will be those that teach people to work with AI — not around it,” Eivers said.

About Datatonic 
Datatonic is a global Data and AI consultancy and 10-time Google Cloud Partner of the Year, helping enterprises turn data and AI into clear, measurable business outcomes. As an end-to-end partner, Datatonic drives rapid transformation across strategy, architecture, deployment, enablement, and continuous optimization, empowering organizations to scale AI impact. Learn more at datatonic.com.

References:

  • Gartner. Gartner Predicts Over 40% of Agentic AI Projects Will Be Canceled by End of 2027. June 25, 2025.
  • Estrada, Sheryl. MIT Report: 95% of Generative AI Pilots at Companies Are Failing. Fortune, Aug. 18, 2025.
  • IDC & Lenovo. CIO Playbook 2025: It’s Time for AI-nomics. 2025.
  • Datatonic. GenOps at Vodafone on Google Cloud. Case study.
  • Datatonic. Reducing Invoice Processing Costs with BigQuery, DocAI and GenAI. Case study.

Media Inquiries: 
Karla Jo Helms
JOTO PR
727-777-4629
jotopr.com

Tineco Appoints Swerve Strategic as U.S. Agency of Record

By
Advertorial Desk
-

SEATTLE, Feb. 10, 2026 /PRNewswire/ — Tineco, a global leader in smart home cleaning solutions, today announced the appointment of Swerve Strategic as its official U.S. Agency of Record. The partnership expands on a long-standing collaboration between the two teams, following Swerve Strategic’s successful role as Tineco’s Agency of Record in Canada since 2020.

Tineco Appoints Swerve Strategic as U.S. Agency of Record
Tineco Appoints Swerve Strategic as U.S. Agency of Record

This appointment marks an important milestone in Tineco’s continued growth in the U.S. market and reflects the brand’s commitment to strengthening its communications, media engagement, and brand presence across key consumer touchpoints. As Agency of Record, Swerve Strategic will lead Tineco’s U.S. public relations and communications efforts, including brand storytelling, media relations, influencer engagement, and integrated campaign support.

Tineco has earned strong recognition in the U.S. for its innovative smart home cleaning solutions, particularly its category-leading wet and dry floor care technology designed to deliver powerful performance for real-world household needs. With a focus on intuitive design, reliable functionality, and everyday usability, Tineco continues to support modern households—especially busy families and pet owners—with smarter, more efficient cleaning experiences.

“As Tineco continues to grow in the U.S., it’s important that our communications reflect not only the innovation behind our products, but also how they fit naturally into modern everyday living,” said Bill Song, Director of International Brand and Marketing at Tineco. “Our collaboration with Swerve Strategic has delivered strong results in Canada, and we’re pleased to extend this partnership to the U.S. as we continue building a more connected, lifestyle-driven dialogue with consumers.”

Through this partnership, Swerve Strategic will support Tineco’s mission to bring thoughtful innovation to U.S. consumers—helping make home cleaning simpler, more efficient, and better aligned with modern lifestyles.

All U.S. media inquiries related to Tineco marketing and communications may be directed to
TinecoMedia@SwerveStrategic.com.

About Tineco
Tineco (“tin-co”) was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 23 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit https://us.tineco.com/.

About Swerve Strategic
Swerve Strategic is a leading integrated communications agency specializing in full-funnel marketing solutions that drive brand success. With expertise across PR, influencer marketing, digital marketing, and more, Swerve Strategic helps brands navigate the evolving media landscape and connect with audiences at every stage of the customer journey. For more information, visit: https://swervestrategic.com/.

 

“See the Stability”: Vernal Launches Core3 Standing Desk with Public “Test Report” Performance Data

By
Advertorial Desk
-

LAS VEGAS, Feb. 10, 2026 /PRNewswire/ — In a standing desk market frequently dominated by inflated specifications and parameter metrics, Vernal is taking a bold step toward total transparency. Today, the brand challenges this status quo with the launch of the Vernal Core3, accompanied by the “Test Report”.

Under the campaign theme “See the Stability”, Vernal is shifting the focus from theoretical maximums to measurable performance. The brand’s guiding principle, “We publish what we test”,  promises total transparency regarding what was tested and how it was measured. To validate this commitment, the Core3’s critical performance metrics have been rigorously verified by independent third-party organizations, including SGS, TÜV Rheinland, and UL. These results are publicly available in the Test Report, launching alongside the product.

Vernal Core3 Standing Desk
Vernal Core3 Standing Desk

In the Test Report, Vernal validates three core standing desk experiences to deliver its brand promise of ‘Peace of Mind’:

1. Stability Backed by Data: Desk wobble disrupts cognitive focus. While many brands rely on marketing visuals to promote stability, Vernal has chosen to directly publish wobble displacement data measured at a crucial standing height of 128 cm in the report. The Core3 is proven to maintain a rigid structure even at this extension, minimizing distractions and supporting users’ daily workflow.

2. True Lifting Capacity without Speed Loss: Vernal chooses to list a 160 kg rated lifting capacity of that guarantees real-world performance instead of promoting the maximum static load capacity. Tests confirm that even under full load, the desk maintains consistent lifting speed and whisper-quiet operation below 50 dB, ensuring smooth transitions.

3. Transparent Safety Records: In a continued commitment to transparency, Vernal tested the anti-collision system against multiple object types. The Test Report records the success rates of triggering the rebound mechanism when encountering resistance from various obstructions, ensuring users understand the desk’s true safety reliability.

“Vernal prioritizes honesty over market competition. Consumers deserve to know exactly what the standing desk they bring home is really like”, said a Vernal spokesperson. “Through the Test Report, Vernal wants to show that the Core3 is built for your peace of mind”.

The Vernal Core3 and the full Test Report are available starting today at vernalspace.com.

About Vernal: Vernal is a workspace brand designed for home life, dedicated to enhancing the home office experience, delivering stability, peace of mind, and sustainability over long-term use.
Media Contact: media@vernalspace.com

On Site: “2026 China Forum on Source Innovation in New Drug Discovery” Concludes Successfully

By
Advertorial Desk
-

SHANGHAI, Feb. 10, 2026 /PRNewswire/ — As China’s new drug R&D enters the “deep waters” of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. The industry must pivot—returning to the very starting point of innovation.

Yet a critical question remains: how can scientific discoveries cross the “Valley of Death” of industrial translation? How can a sustainable ecosystem of original innovation be continuously cultivated? The answer lies not in isolated efforts, but in cross-disciplinary co-creation.

Against this backdrop, Sanyou Bio, in partnership with Tongxieyi, jointly hosted the “2026 China New Drug Source Innovation Forum” on February 8, 2026, in Shanghai. The forum bought together visionary leaders from academia, industry, and the investment communities to explore breakthrough pathways for source innovation in new drug development and to envision the future of the biopharmaceutical industry.

The forum addressed cutting-edge fields and topics ranging from AI-driven drug discovery and personalized immunotherapies, to next-generation ADC design and human micropeptidome research; from university–industry translational collaboration to asset value re-evaluation. Under the theme “Nurturing Innovation at Its Source”, this intellectual gathering served as a platform for cross-sector collaboration, while also witnessed the official launch of the Clicklinks Innovation Hub for Original Drug Discovery, and the signing of multiple strategic partnerships.

The forum was fully livestreamed on Tongxieyi’s WeChat Channel and WeChat Mini Program with online viewership exceeding 30,000.

01 | Opening Address

Kai-Xian Chen
Research Fellow, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

China’s biopharmaceutical industry has evolved from a model dominated by generic-drug to one increasingly driven by breakthroughs in original innovation medicines. Supported by strong national policies, it has emerged as an important growth engine of global pharmaceutical innovation. Original innovative drugs now represent the core driving force of industry development and a key pillar of the Healthy China strategy.

Nevertheless, challenges remain in areas such as source innovation, core technologies, translational efficiency, and industry–academia collaboration. These challenges call for concerted efforts across the entire ecosystem. The development of original innovative medicines relies on the integration of advanced technologies, enabling platforms, high-level talent, and close collaboration among industry, academia, and research institutions.

The Shanghai Institute of Materia Medica, Chinese Academy of Sciences is committed to deepening cooperation with all stakeholders, focusing on major disease areas, and driving the industry’s transition from “following” to “running alongside” and ultimately “leading” global innovation. Through these efforts, we aim to support the globalization of China’s homegrown innovative biologics and promote the high-quality industry development.

02 Keynote Presentations

Guojun Lang
Founder & CEO, Sanyou Bio

Making Innovative Biologic Drug Development Accessible to All

Over the past decade, Sanyou Bio has remained deeply committed to the development of innovative biologics. Anchored by its intelligent Super-Trillion Antibody Library (STAL), now exceeding 11 trillion in library compacity, and proprietary AI-STAL technology, the company has built an integrated, intelligent R&D platform that seamlessly combines wet-lab and dry-lab capabilities. This platform underpins a dual-engine growth model driven by R&D innovation and commercial operations.

To date, Sanyou Bio has served over 2,000 clients worldwide and delivered over 2,000 projects. Among more than 60 collaborative programs, over 10 have successfully completed IND (Investigational New Drug) filings, and three have advanced to Phase III clinical trials.

Looking ahead, Sanyou Bio will advance its “5-5 Strategic Initiative”, leveraging the combined power of AI technologies and super-trillion-scale libraries, to establish the Clicklinks Innovation Hub for Original Drug Discovery. Through close collaboration with government, industry, academia, research institutions, and healthcare partners, Sanyou Bio aims to build a robust innovation ecosystem – advancing its mission of “Making innovative biologic drug development accessible and achievable for all”.

Hua Mao
Partner & Managing Director, Greater China
Frost & Sullivan

Global Innovative Drug Market Overview

Driven by multiple factors such as regulatory reform in drug approval and increased capital investment, China has seen a rapid surge in the number of innovative drugs under development. China has now surpassed Europe to become the world’s second-largest hub for innovative drug pipelines, trailing only the United States. At the same time, pipeline quality has improved significantly, with a rising proportion of First-in-Class (FIC) assets, particularly in advanced therapies such as cell and gene therapies (CGT) and nucleic acid-based drugs.

Although global and Chinese biotech investment and financing activity in innovative drugs has experienced fluctuations, biologics—including monoclonal antibodies, ADCs, and CGT— have remained highly favored. In China business development and licensing transaction market remain active, with companies increasingly prioritizing internationalization strategies. Overall, the industry is characterized by a biologics-driven growth model and an accelerating pace of global Expansion.

Zhimin Lv
Academician, Academia Europaea

University–Industry Collaboration to Advance Translational Research

Established in 2014, the Zhejiang University Institute of Translational Medicine is a new-generation research institute dedicated to bridging basic research and clinical medicine and accelerating the industrialization of biologic innovation. The institute operates under a co-construction, co-management, and resource-sharing model in collaboration with seven affiliated hospitals of Zhejiang University School of Medicine, and is supported by a high-caliber multidisciplinary talent team.

The institute has achieved significant outcomes in scientific research projects, academic publications, translational achievements, and clinical studies. Through close collaboration with industry partners, it conducts diversified drug R&D programs spanning antibodies, peptides, and small molecules, targeting a wide range of diseases including oncology, metabolic liver diseases, autoimmune disorders, and neurodegenerative diseases. These efforts collectively promote the advancement of pharmaceutical R&D and the sustainable development of the biologic industry.

Bin Li
Research Fellow, Shanghai Institute of Immunology

Current Status and Future Perspectives of Personalized Immunotherapy

Personalized immunotherapy has emerged as a major frontier in oncology. Its therapeutic efficacy is largely determined by the immune characteristics of the tumor microenvironment. Advances in AI and spatiotemporal multi-omics are now providing critical support for improving precision and personalization in immunotherapy.

Our research team has long been dedicated to the study of FOXP3+ Treg research and has proposed the Immunological Oscillation Theory. By integrating a multi-omics analytical framework established through tripartite collaboration, we aim to facilitate the translation of Treg-based therapies from fundamental research to clinical application, ultimately contributing to the advent of single-cell–level precision medicine.

Tianyi Qiu
Young Principal Investigator, Fudan University

Accelerating Large-Molecule Drug Discovery and Design with Artificial Intelligence

Mutation escape remains a key factor affecting efficacy of antibodies and vaccines. To address three core challenges—immunogenicity prediction, antigen similarity assessment, and high-throughput design and screening—our team has developed the SEPPA series of epitope prediction algorithms and the CE-BLAST antigen similarity prediction algorithm, achieving superior accuracy than conventional tools.

We have also established a high-throughput computational workflows, applying it to antibody and vaccine design case studies for SARS-CoV-2, norovirus, and influenza. Experimental validation has confirmed the effectiveness of these designs, resulting in a comprehensive technology pipeline that spans from pathogen analysis to antibody/vaccine discovery and optimization.

Hailiang Zheng
Vice President, R&D, Sanyou Bio

Application of AI-STAL in Source Innovation for New Drug Discovery

The global antibody drug market is expanding rapidly, and generative AI is increasingly empowering R&D. Traditional antibody discovery, however, faces challenges such as long development cycles. The AI-STAL establishes a comprehensive technology pathway from de novo design to in vitro and in vivo validation, centered on an integrated wet-lab and dry-lab workflow. It is supported by a super-trillion antibody library and an intelligent R&D platform, providing a robust foundation for high-efficiency discovery. Looking ahead, this technology is expected to transform biologics R&D toward precise, on-demand design, accelerating innovation at the very source of new drug development.

Xin Xie
Deputy Director, National Center for Drug Screening

New Drug Discovery Targeting G Protein-Coupled Receptors (GPCRs)

G protein-coupled receptors (GPCRs) represent the largest family of membrane protein receptors in the human body, playing key roles numerous physiological processes. Dysregulation of GPCR function is closely associated with a wide range of diseases, making GPCRs a central target family in drug discovery. Currently, approximately 30–40% of approved drugs globally target GPCRs, covering therapeutic areas such as neurology, endocrinology, immunology and metabolism.

In 2025, sales of GPCR-targeted anti-obesity drugs semaglutide and tirzepatide are each achieved to exceed USD 35 billion, highlighting the substantial value of GPCRs in new drug discovery.

The speaker provides an overview of GPCR structure and signal transduction characteristics, as well as new drug screening methodologies. As a case study, GPR84, a GPCR with key role in immune and inflammatory disease, is discussed. This includes research on its functions in colitis, lung injury, and atopic dermatitis, the discovery and optimization of novel structural ligands, and ongoing new drug development efforts targeting colitis and atopic dermatitis.

Guoqing Cao
Chairman, Minghui Pharma

Next-Generation ADC Molecule Design

The development of innovative drugs is inherently long and high-risk, relying on scientific innovation, technological support, outstanding teams, and perseverance. ADC represents a major breakthrough in cancer therapy, now expanding from hematologic malignancies to solid tumors. Their rapid development is driven by multidimensional technological upgrades, including targets, targeting agents, linkers, and payloads.

Minghui’s SuperTopoi ADC platform demonstrates significant advantages, featuring highly efficient proprietary payloads, clinically validated linkers, and optimized antibody engineering, achieving strong safety profiles and antitumor efficacy. Among its lead candidates, MHB088C has shown remarkable efficacy and excellent safety and tolerability across multiple tumor clinical studies, with a favorable benefit-risk profile, and its clinical development is progressing steadily.

Yujie Xia
Product Director, Sanyou Bio

Launch of Clicklinks Original Innovative Drug Innovation Hub

The Clicklinks Original Innovative Drug Innovation Hub is founded on the principles of openness and efficiency, industry collaboration, mutual benefit and win-win outcomes, and value realization.

It is committed to building a sustainable platform that integrates upstream and downstream partners and accelerates the translation of research outcomes.

Powered by AI-STAL, the Clicklinks focuses on nine major disease areas and over ten types of innovative molecular modalities, ensuring precise alignment with unmet clinical needs.

Its development aims to foster global ecosystem collaboration and establish deeply integrated strategic partnerships, supporting partners in the continuous development of original innovative drugs. Our vision is to cultivate a thriving “Innovation Rainforest”, where an open ecosystem empowers partners across all dimensions of drug discovery and development.

03 Signing Ceremony

The vitality of source innovation lies not only in breakthroughs in cutting-edge science, but also in the smooth translation from laboratory research to industry and the co-building of an innovation ecosystem.

At this forum, the “AI-STAL–Driven Clicklinks Original Innovative Drug Innovation Hub Signing Ceremony” was officially held with great prominence. Fourteen distinguished representatives from academia and industry jointly took the stage to witness this milestone. They are:

Hongchen Gu: President, Hefei Early Screening Institute, Shanghai Jiao Tong University
Naping Tang: Vice President, InnoStar
Weiqin Ni: Deputy General Manager, Liferiver
Kai Tan: General Manager, Dragon Sail Pharmaceutical
Shumin Wang: General Manager, TransReco
Henghao Xu: General Manager, Yugong Bio
Linglong Zou: General Manager, Kanwhish Biotech
Feng Tan: General Manager, NovoPro
Guozhen Xing: General Manager, AnLing Biomed
Zhenghai Li: General Manager, NephroMedicine
Dongxiao Feng: Deputy General Manager, Shanghai Model Organisms Center (SMOC)
Donglin Sun: Deputy General Manager, Acemab
Yichun Luo: Medical Director, Revvity
Guojun Lang: Founder & CEO, Sanyou Bio

04 Roundtable Dialogues

Entrepreneurs and Scientists in discussion on the Ecosystem of Original Innovative Drug R&D
Zhenze Hu (Moderator): Founder, ZhenSighti
Dongzhou Liu: Chief Strategy Officer (CSO), Huadong Medicine
Qi He: Co-Founder & CEO, TandemAI
Yiwei Chu: Professor, Fudan University, Vice President, Chinese Society of Immunology (CSI)
Xuanhui Xie: Managing Partner, TVM Capital / ValueSeek Ventures
Yongqi Chen: Founder & CEO, Resproly
Sunxing Qin: Chairman, LePure Biotech

China’s ecosystem for innovative drugs has taken shape and already demonstrates significant achievements. Strengths are particularly notable in CRO/CDMO services and early-stage R&D, with active outbound licensing and collaboration. However, several key gaps remain. Payment and reimbursement systems are underdeveloped, translational pathways from basic research to Proof of Concept (POC) are incomplete, and there is a shortage of talent, insufficient global commercialization capabilities, and limited collaboration across the industry chain.

In terms of early-stage innovation risk, the translation of academic research remains challenging, necessitating coordinated efforts among enterprises, investors, and government. Large pharmaceutical companies are increasingly willing to engage in breakthrough early-stage projects. On the non-technical side, low tolerance for failure, decision-making inefficiencies, and misallocation of resources have created competitive “overwork” pressure, which hinder ecosystem efficiency.

Over the next 5–10 years, the ecosystem is expected to enter a phase of optimization, integration, and deeper globalization. Recognition of clinical data will increase, differentiated innovation will become mainstream. China is poised to produce globally leading pharmaceutical companies, achieving a leap from high competition to high-quality innovation.

Source Innovation and the Re-Evaluation of China’s Innovative Drug Assets
Zengjiang Cheng (Moderator): Vice Chairman, China Pharmaceutical Industry Promotion Association Founder & Chairman, Tongxieyi
Tao Ru: Managing Director, Shanghai Guotou Pioneer Private Equity Fund
Jian’er Yao: Chairman, Tellgen Corporation
Yu Zhou: Partner, Huatai Zijin Fund
Jia Li: Partner, Longshine Investment
Jie Chen: Expert, Technology Finance DepartmentBank of Communications
Suyang Wang: General Manager, Technology Finance Division Shanghai Rural Commercial Bank

China’s innovative drug assets have transitioned from imitation to differentiated, engineering-driven innovation, attracting growing international attention. BD transaction upfront payments have grown counter-cyclically. Nevertheless, challenges remain, including homogeneous competition, valuation dependence on oversea markets, and tighter Hong Kong IPO policies, making high-quality differentiated assets the core of the market.

On the international front, supply is increasing, but clinical value and differentiation remain critical. Overseas companies often acquire Chinese assets for efficiency reasons, highlighting the need to enhance global commercialization capabilities in the long term. From a capital perspective, investment institutions urge the market to avoid following trends, remain patient, and focus on first-in-class innovation. Banks are supporting innovative drugs across the full chain through credit loans, equity-linked products, and clinical loans, emphasizing early evaluation of team and data, and in some cases reducing personal joint liability. These measures provide both timely support and strategic capital reinforcement, making financial backing more effective and targeted.

In terms of source innovation, universities and research institutes focus on fundamental target discovery, while enterprises lead engineering-based translation and implementation. Effective industry–academia–research collaboration, along with tolerance for innovation risk, is essential to foster a healthy and sustainable ecosystem.

05 Closing Remarks

Zengjiang Cheng
Vice Chairman, China Pharmaceutical Industry Promotion Association
Founder & Chairman, Tongxieyi

The forum featured nine keynote presentations and two roundtable discussions, bringing together leading experts from China’s top scientific institutions and universities. In-depth exchanges focused on global new drug R&D, AI-driven drug discovery, next-generation ADC technologies, and personalized medicine, highlighting China’s positive trajectory from “following” to “running alongside” and even “leading” in these cutting-edge fields. Notably, significant internationally competitive achievements and teams have emerged in key areas such as AI-driven drug development and precision medicine.

During the forum, Sanyou Bio signed strategic agreements with multiple partners to officially launch the Clicklinks Innovative Drug Innovation Hub, marking a major step forward in industry–academia–research collaboration. We look forward to Sanyou Bio achieving new milestones over the next decade, supporting the next wave of innovation in China’s biopharmaceutical innovation.

Wishing everyone success and momentum in the Year of the Horse.

About Sanyou

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical enterprise driven by its super-trillion molecule library and artificial intelligence technology, with the mission of “making innovative biologics R&D easy for clients worldwide”.

Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub. The company is centered on its AI-driven super-trillion antibody library (AI-STAL) and supported by its world-leading, integrated and intelligent R&D platform for innovative biologics development that seamlessly combines in silico and wet-lab capabilities. Sanyou drives the global development and industrialization of innovative new drugs through diversified business models.

Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.

Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages.

The company has filed over 130 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

KPS CAPITAL PARTNERS TO ACQUIRE THE WELLS COMPANIES, INC.

By
Advertorial Desk
-

Leading Manufacturer and Installer of Above-Grade Architectural and Structural Precast Concrete Solutions

NEW YORK, Feb. 10, 2026 /PRNewswire/ — KPS Capital Partners, LP (“KPS”) announced today that, through a newly formed affiliate, it has signed a definitive agreement to acquire The Wells Companies, Inc. (“Wells” or the “Company”), a leading designer, manufacturer and installer of above-grade architectural and structural precast concrete solutions in the United States. Financial terms of the transaction were not disclosed. Completion of the transaction is expected in the first quarter of 2026 and is subject to customary closing conditions and approvals.

Wells is a leading provider of above-grade precast concrete solutions in the United States, serving a broad range of end-markets and customers nationwide. As a fully integrated platform, the Company has one of the most comprehensive above-grade precast portfolios in the industry, offering end-to-end capabilities including design assist, engineering services, manufacturing and on-site installation and finishing. Headquartered in Albany, Minnesota, Wells employs approximately 2,700 people and operates 13 strategically located manufacturing facilities across the United States.

Ryan Harrison, Partner and Co-Head of KPS Mid-Cap Investments, said, “We are excited to acquire Wells, a market leader in the above-grade precast concrete industry in the U.S. The Company’s leadership position is driven by its comprehensive product portfolio, differentiated value-added services capabilities, long-tenured customer relationships and a best-in-class manufacturing footprint. Wells’ manufacturing expertise, commitment to quality and strong customer relationships, combined with KPS’ strategic, operational and financial resources provide an ideal platform for future growth. We look forward to partnering with Chief Executive Officer Dan Juntunen and the rest of the Wells team to aggressively expand the business both organically and through strategic acquisitions.”

Dan Juntunen, Chief Executive Officer of Wells, said, “KPS, with its demonstrated track record of manufacturing excellence and significant building products experience, is the ideal partner for Wells as we enter this next phase of growth. We look forward to working closely with KPS and our talented team to expand our industry leadership and to continue delivering high-quality products that provide significant value for our customers. The Company is well-positioned to benefit from strong industry tailwinds from the growing adoption of precast concrete solutions across diverse construction applications and leveraging our unique market position.”

Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to KPS. Piper Sandler and Taft, Stettinius and Hollister LLP served as financial advisor and legal counsel, respectively, to Wells.

About Wells
The Wells Companies, Inc. is one of the nation’s leading full-service prefabricated building solutions providers with a focus on above-grade structural and architectural precast concrete solutions. With over 70 years of expertise, Wells works alongside design and construction partners, adding value by solving challenges, reducing risk and establishing trust from project onset to completion. With an eye to the future, Wells advanced research, manufacturing and building practices are continuously raising standards for innovation and efficiency in the built environment. The Wells team creates landmarks across the U.S., transforming communities and helping businesses and individuals thrive. For more information about Wells, visit www.wellsconcrete.com.

About KPS Capital Partners
KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with $19.5 billion of assets under management (as of September 30, 2025). For nearly three decades, the Partners of KPS have worked exclusively to realize significant capital appreciation by making controlling equity investments in manufacturing and industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing. KPS creates value for its investors by working constructively with talented management teams to make businesses better, and generates investment returns by structurally improving the strategic position, competitiveness, and profitability of its portfolio companies, rather than primarily relying on financial leverage. The KPS Funds’ portfolio companies have aggregate annual revenues of approximately $21.2 billion, operate 202 manufacturing facilities in 21 countries, and have approximately 55,000 employees, directly and through joint ventures worldwide (as of September 30, 2025). The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.

KPS Mid-Cap focuses on investments in the lower end of the middle market. KPS Mid-Cap targets the same type of investment opportunities and utilizes the same investment strategy that KPS’ flagship funds have for over three decades. KPS Mid-Cap leverages and benefits from KPS’ global platform, reputation, track record, infrastructure, best practices, knowledge and experience. The KPS Mid-Cap investment team is managed by Partners, Pierre de Villeméjane and Ryan Harrison, who lead a team of experienced and talented professionals.

 

DXC Completes Enterprise-Wide Amazon Quick Deployment and Launches New Practice to Help Accelerate AI Adoption

By
Advertorial Desk
-
  • DXC proves AI at real enterprise scale through its own global deployment of Amazon Quick, supporting 115,000 employees across 70 countries.
  • New DXC Amazon Quick Practice helps customers securely deploy and operationalize AI across complex, multivendor enterprise ecosystems.
  • DXC’s Customer Zero approach validates new technologies internally first, enabling faster and more confident customer adoption.

ASHBURN, Va., Feb. 10, 2026 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced the completion of DXC’s enterprise-wide deployment of Amazon Quick, the agentic AI-powered digital workspace, across its global workforce of 115,000 employees operating in 70 countries and the launch of the DXC Amazon Quick Practice, a new business unit focused on helping customers worldwide operationalize AI at scale across multivendor enterprise ecosystems.

DXC Completes Enterprise-Wide Amazon Quick Deployment and Launches New Practice to Help Accelerate AI Adoption
DXC Completes Enterprise-Wide Amazon Quick Deployment and Launches New Practice to Help Accelerate AI Adoption

The announcement represents one of the largest enterprise deployments of Amazon Quick to date and underscores DXC’s Customer Zero approach. By first operating new technologies internally at true enterprise scale, under real-world security and governance requirements, DXC validates what works before helping customers deploy and scale those capabilities in their own environments. Drawing on the same experience, operating models, and governance frameworks used inside DXC, the company helps customers move AI from pilot programs into full scale production with greater speed and confidence.

Enterprise AI, Proven Inside DXC

DXC deployed Amazon Quick to improve how its employees access information, collaborate, and deliver work across a highly distributed, global enterprise in all lines of its business. The platform connects employees to trusted data across systems while maintaining enterprise-grade security, access controls, and compliance requirements. As part of the rollout, DXC introduced an AI Advisor Agent that provides employees with a single access point for AI-related knowledge, tools, prototypes, and feedback and is now used by more than 40,000 engineers. The rollout also includes role-based AI advisors, such as a Supply Chain Advisor that delivers fast, trusted operational guidance by connecting employees directly to validated knowledge, enabling teams to move faster with confidence.

By reducing friction across disparate systems and simplifying access to information, the deployment has helped speed up decision-making, improve productivity, and accelerate the building of ideas into real customer solutions. The initiative is led by DXC’s Chief Digital Information Officer Russell Jukes, reflecting a tightly aligned execution model across technology, delivery, and operations that unifies DXC’s digital, information, and AI agenda to accelerate enterprise scale AI. Deployed first within DXC, the approach is designed to translate directly into how DXC supports customer AI transformation at scale.

“Deploying Amazon Quick across DXC’s global workforce gave us the opportunity to pressure-test at true enterprise scale. We’ve seen firsthand how AI, when connected to the way people work and the processes they rely on, can reduce friction, improve decision-making, and help teams operate more effectively with the right guardrails in place. That experience now directly informs how we help our customers move beyond pilots and activate AI across their enterprises.” – Russell Jukes, Chief Digital Information Officer, DXC

Launch of the DXC Amazon Quick Practice

Building on its proven internal deployments, DXC is launching the DXC Amazon Quick Practice to help enterprises deploy AI with greater speed, confidence, and control. Powered by more than 10,000 Amazon-certified professionals with over 1,000 trained and certified across Amazon AI specializations and DXC’s enterprise AI delivery programs, the practice combines proven deployment methodologies, Amazon-native frameworks, and governance models validated within DXC’s own operations. This foundation, attested by the achievement of multiple AWS AI competencies, enables enterprises to move beyond experimentation and responsibly operationalize AI, delivering measurable productivity gains while maintaining enterprise-grade security, compliance, and reliability.

Cross-functional teams of AI architects, automation designers, and adoption leads partner with customers to identify high-impact use cases and rapidly deploy secure, pre-built AI capabilities spanning AI-powered research, advanced business intelligence, and agent-ready automation. Designed to scale with enterprise needs, the practice also supports co-investment with Amazon in targeted industry solutions across sectors such as financial services, insurance, and manufacturing, accelerating time to value and driving measurable business outcomes.

“Many enterprises are eager to use AI but struggle to turn pilots into real business impact. The DXC Amazon Quick Practice combines our enterprise delivery experience and proven operating models to help customers deploy AI responsibly, accelerate modernization, and achieve measurable results. This is more than a partnership, it’s a launchpad for AI-powered enterprise transformation, with a focus on making AI practical, scalable, and embedded into day-to-day operations, not just another tool sitting on the sidelines.”
– Ramnath Venkataraman, President of Consulting & Engineering Services, DXC

 

“Amazon Quick is designed to enable enterprise-grade AI directly where people work. DXC has proven the power of Quick by successfully integrating into the day-to-day workflows of 115,000 employees across 70 countries. Together, through the DXC Amazon Quick Practice, we’re well positioned to provide enterprises a proven, confident path to roll out AI at scale within the systems and data they already use.” – Jose Kunnackal John, Director, Amazon Quick

The DXC Amazon Quick Practice draws on DXC’s experience deploying and operating AI across a global enterprise to help customers move beyond pilots and embed agentic AI into day-to-day operations. Building on DXC’s longstanding partnership with Amazon, the practice supports enterprises navigating growing AI complexity and rising expectations by integrating and managing AI solutions within existing environments, accelerating adoption, delivering measurable results, and operationalizing AI securely and responsibly.

About DXC

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world’s most complex technology estates. Learn more on dxc.com.

About AWS

Amazon Web Services (AWS) is guided by customer obsession, pace of innovation, commitment to operational excellence, and long-term thinking. By democratizing technology for nearly two decades and making cloud computing and generative AI accessible to organizations of every size and industry, AWS has built one of the fastest-growing enterprise technology businesses in history. Millions of customers trust AWS to accelerate innovation, transform their businesses, and shape the future. With the most comprehensive AI capabilities and global infrastructure footprint, AWS empowers builders to turn big ideas into reality. Learn more at aws.amazon.com and follow @AWSNewsroom.

Media Contact: DXC, Ashley Houk-Temple, Media Relations, ashley.houktemple@dxc.com

DeskIn Redefines Remote Access for Families: One-Click Tech Support for Kids, Partners, and Parents from Anywhere

By
Advertorial Desk
-

SINGAPORE, Feb. 10, 2026 /PRNewswire/ — DeskIn, the flagship remote access software from Zuler Technology Pte. Ltd, is designed to make everyday family support simple, secure, and stress-free.

For families living apart, helping loved ones with technology can be frustrating. Traditional remote access tools often suffer from pixelated screens, complicated set ups, and laggy controls making tasks like tutoring children, sharing photos, or guiding parents with technology feel frustrating rather than meaningful. With a single click, DeskIn turns any device into a smooth, intuitive bridge for seamless family support across distances.

DeskIn helps families remotely: from troubleshooting seniors' phones to sharing screens, tutoring homework, and managing kids' device usage.
DeskIn helps families remotely: from troubleshooting seniors’ phones to sharing screens, tutoring homework, and managing kids’ device usage.

Key Scenarios for Families

  • Elderly Tech Support: Guide parents through device issues with clear visuals, remote control, and voice chat.
  • Screen Sharing App: Browse photo albums or watch videos together in high definition, as if you are side-by-side.
  • Remote Learning and Tutoring: Help with kid’s homework or teach new skills through live screen sharing, audio chat, and annotation.
  • Parental Control: Assist minors in managing screen time and browsing websites.
  • Repurpose Old Devices: Turn unused phones into security cameras to check in on loved ones or pets.

DeskIn Core Technical Advantages
DeskIn supports cross-platform remote control and delivers a comprehensive, engaging, and secure experience.

  • Crystal-Clear Visuals: Lossless 4:4:4 color and up to 4K streaming.
  • Real-Time Control: Input under 40ms latency.
  • Root-free Android Control: Operates family Android devices remotely without rooting.
  • Complete Features: Integrated audio calls, screen annotation, high-speed file transfer, and remote camera access.

Secured Remote Access Built for Families

1) Bank-grade Encryption: Utilizes end-to-end AES-256 encryption.

2) Secure Connections: Set up dedicated whitelists and secure passwords for devices.

3) Permission Management: You can control the remote party’s access to the camera, microphone, or files at any time.

4) Instant Privacy Protection: One click to enable privacy screen and auto-lock screen to safeguard family privacy.

DeskIn Plan Promotion

Until February 28, 2026, subscribe to any DeskIn personal annual plan with the promo code [FAMILY26] to enjoy a 20% discount.

No matter where you are, let DeskIn bridge care and support for you and your family in one click.

About DeskIn

Installed on over 180 million devices and serving 40 million+ users, DeskIn leverages its proprietary ZeroSync® engine to deliver a superior remote access experience – so anyone can share, create, play, and work seamlessly.

For more information, visit: https://deskin.io/

1...1,2931,2941,295...6,715Page 1,294 of 6,715